New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer
The gastrointestinal tract represents one of the largest interfaces between the host and environmental factors. It contains a vast and complex community of microbes, forming what is collectively known as the microbiota. This gut microbiota plays a pivotal role in the maintenance of health, and '...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2019-09, Vol.459, p.186-191 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 191 |
|---|---|
| container_issue | |
| container_start_page | 186 |
| container_title | Cancer letters |
| container_volume | 459 |
| creator | Ezzaidi, Niama Zhang, Xiang Coker, Olabisi Oluwabukola Yu, Jun |
| description | The gastrointestinal tract represents one of the largest interfaces between the host and environmental factors. It contains a vast and complex community of microbes, forming what is collectively known as the microbiota. This gut microbiota plays a pivotal role in the maintenance of health, and 'dysbiosis' of the gut microbiota, commonly considered as perturbation of microbiota diversity and composition, has been associated with intestinal and extra-intestinal diseases, including non-alcoholic fatty liver disease (NAFLD) and its associated hepatocellular carcinoma (NAFLD-HCC).
In this review, we highlight microbiota dysbiosis and the microbiota-host interactions that link to the pathogenesis of NAFLD and NAFLD-HCC. We discuss the potential therapeutic implications of the gut microbiota in the progression of NAFLD-HCC.
•Gut microbiota plays a mechanistic role in non-alcoholic fatty liver disease (NAFLD). .•Gut microbiota profile is associated with HCC development in NAFLD patients.•Microbe-generated metabolites contribute to NAFLD and NAFLD-HCC pathogenesis. .•Host immune response is involved in gut microbiota-regulated NAFLD and NAFLD-HCC. .•Gut microbiota acts as a potential therapeutic target for NAFLD. |
| doi_str_mv | 10.1016/j.canlet.2019.114425 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2255719222</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383519303477</els_id><sourcerecordid>2255719222</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-1b4cc3b1d8c42c6fba5d5de622d5df8b30139c88ebb6179411f2ae06220ec4553</originalsourceid><addsrcrecordid>eNp9kEuP1DAQhC0EYoeFf4CQJc4Z3H5MkgsSWvGSVnCBs-XYnZ0eZeLBdhbtib-OhwwcOfWhv6ruKsZegtiCgN2bw9a7ecKylQL6LYDW0jxiG-ha2bR9Jx6zjVBCN6pT5oo9y_kghDC6NU_ZlQLojNT9hv36gj85zZnu9iVzNwde9pjcCZdCntPxNJF3heLM48jvlsKP5FMcKBZXZXyOc-MmH_excnx0pTzwie4x8UAZXcY_lnS2zjl6cgXDBajfe0zP2ZPRTRlfXOY1-_7h_bebT83t14-fb97dNl71ojQwaO_VAKHzWvrdODgTTMCdlHWM3aAEqN53HQ7DDtpeA4zSoah7gV4bo67Z69X3lOKPBXOxh7ikuZ60UhrTQi-lrJReqZox54SjPSU6uvRgQdhz6_Zg19btuXW7tl5lry7my3DE8E_0t-YKvF0BrBHvCZPNnrDmD5TQFxsi_f_Cb3WClxA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2255719222</pqid></control><display><type>article</type><title>New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Ezzaidi, Niama ; Zhang, Xiang ; Coker, Olabisi Oluwabukola ; Yu, Jun</creator><creatorcontrib>Ezzaidi, Niama ; Zhang, Xiang ; Coker, Olabisi Oluwabukola ; Yu, Jun</creatorcontrib><description>The gastrointestinal tract represents one of the largest interfaces between the host and environmental factors. It contains a vast and complex community of microbes, forming what is collectively known as the microbiota. This gut microbiota plays a pivotal role in the maintenance of health, and 'dysbiosis' of the gut microbiota, commonly considered as perturbation of microbiota diversity and composition, has been associated with intestinal and extra-intestinal diseases, including non-alcoholic fatty liver disease (NAFLD) and its associated hepatocellular carcinoma (NAFLD-HCC).
In this review, we highlight microbiota dysbiosis and the microbiota-host interactions that link to the pathogenesis of NAFLD and NAFLD-HCC. We discuss the potential therapeutic implications of the gut microbiota in the progression of NAFLD-HCC.
•Gut microbiota plays a mechanistic role in non-alcoholic fatty liver disease (NAFLD). .•Gut microbiota profile is associated with HCC development in NAFLD patients.•Microbe-generated metabolites contribute to NAFLD and NAFLD-HCC pathogenesis. .•Host immune response is involved in gut microbiota-regulated NAFLD and NAFLD-HCC. .•Gut microbiota acts as a potential therapeutic target for NAFLD.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2019.114425</identifier><identifier>PMID: 31185249</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Alcohol ; Antibiotics ; Bacteria ; Chronic illnesses ; Cytokines ; Digestive system ; Drug resistance ; Dysbacteriosis ; Environmental factors ; Fatty liver ; Gastrointestinal tract ; Gut microbiota ; Gut-liver axis ; Hepatocellular carcinoma ; Histology ; Immunity ; Insulin resistance ; Interfaces ; Intestinal microflora ; Intestine ; Liver ; Liver cancer ; Liver diseases ; Metabolism ; Metabolites ; Metabolome ; Microbiota ; NAFLD ; NAFLD-HCC ; Pathogenesis ; Permeability ; Weight control</subject><ispartof>Cancer letters, 2019-09, Vol.459, p.186-191</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><rights>2019. Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-1b4cc3b1d8c42c6fba5d5de622d5df8b30139c88ebb6179411f2ae06220ec4553</citedby><cites>FETCH-LOGICAL-c390t-1b4cc3b1d8c42c6fba5d5de622d5df8b30139c88ebb6179411f2ae06220ec4553</cites><orcidid>0000-0002-3222-5824 ; 0000-0001-5008-2153</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304383519303477$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31185249$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ezzaidi, Niama</creatorcontrib><creatorcontrib>Zhang, Xiang</creatorcontrib><creatorcontrib>Coker, Olabisi Oluwabukola</creatorcontrib><creatorcontrib>Yu, Jun</creatorcontrib><title>New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>The gastrointestinal tract represents one of the largest interfaces between the host and environmental factors. It contains a vast and complex community of microbes, forming what is collectively known as the microbiota. This gut microbiota plays a pivotal role in the maintenance of health, and 'dysbiosis' of the gut microbiota, commonly considered as perturbation of microbiota diversity and composition, has been associated with intestinal and extra-intestinal diseases, including non-alcoholic fatty liver disease (NAFLD) and its associated hepatocellular carcinoma (NAFLD-HCC).
In this review, we highlight microbiota dysbiosis and the microbiota-host interactions that link to the pathogenesis of NAFLD and NAFLD-HCC. We discuss the potential therapeutic implications of the gut microbiota in the progression of NAFLD-HCC.
•Gut microbiota plays a mechanistic role in non-alcoholic fatty liver disease (NAFLD). .•Gut microbiota profile is associated with HCC development in NAFLD patients.•Microbe-generated metabolites contribute to NAFLD and NAFLD-HCC pathogenesis. .•Host immune response is involved in gut microbiota-regulated NAFLD and NAFLD-HCC. .•Gut microbiota acts as a potential therapeutic target for NAFLD.</description><subject>Alcohol</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Chronic illnesses</subject><subject>Cytokines</subject><subject>Digestive system</subject><subject>Drug resistance</subject><subject>Dysbacteriosis</subject><subject>Environmental factors</subject><subject>Fatty liver</subject><subject>Gastrointestinal tract</subject><subject>Gut microbiota</subject><subject>Gut-liver axis</subject><subject>Hepatocellular carcinoma</subject><subject>Histology</subject><subject>Immunity</subject><subject>Insulin resistance</subject><subject>Interfaces</subject><subject>Intestinal microflora</subject><subject>Intestine</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metabolome</subject><subject>Microbiota</subject><subject>NAFLD</subject><subject>NAFLD-HCC</subject><subject>Pathogenesis</subject><subject>Permeability</subject><subject>Weight control</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kEuP1DAQhC0EYoeFf4CQJc4Z3H5MkgsSWvGSVnCBs-XYnZ0eZeLBdhbtib-OhwwcOfWhv6ruKsZegtiCgN2bw9a7ecKylQL6LYDW0jxiG-ha2bR9Jx6zjVBCN6pT5oo9y_kghDC6NU_ZlQLojNT9hv36gj85zZnu9iVzNwde9pjcCZdCntPxNJF3heLM48jvlsKP5FMcKBZXZXyOc-MmH_excnx0pTzwie4x8UAZXcY_lnS2zjl6cgXDBajfe0zP2ZPRTRlfXOY1-_7h_bebT83t14-fb97dNl71ojQwaO_VAKHzWvrdODgTTMCdlHWM3aAEqN53HQ7DDtpeA4zSoah7gV4bo67Z69X3lOKPBXOxh7ikuZ60UhrTQi-lrJReqZox54SjPSU6uvRgQdhz6_Zg19btuXW7tl5lry7my3DE8E_0t-YKvF0BrBHvCZPNnrDmD5TQFxsi_f_Cb3WClxA</recordid><startdate>20190910</startdate><enddate>20190910</enddate><creator>Ezzaidi, Niama</creator><creator>Zhang, Xiang</creator><creator>Coker, Olabisi Oluwabukola</creator><creator>Yu, Jun</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0002-3222-5824</orcidid><orcidid>https://orcid.org/0000-0001-5008-2153</orcidid></search><sort><creationdate>20190910</creationdate><title>New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer</title><author>Ezzaidi, Niama ; Zhang, Xiang ; Coker, Olabisi Oluwabukola ; Yu, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-1b4cc3b1d8c42c6fba5d5de622d5df8b30139c88ebb6179411f2ae06220ec4553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Alcohol</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Chronic illnesses</topic><topic>Cytokines</topic><topic>Digestive system</topic><topic>Drug resistance</topic><topic>Dysbacteriosis</topic><topic>Environmental factors</topic><topic>Fatty liver</topic><topic>Gastrointestinal tract</topic><topic>Gut microbiota</topic><topic>Gut-liver axis</topic><topic>Hepatocellular carcinoma</topic><topic>Histology</topic><topic>Immunity</topic><topic>Insulin resistance</topic><topic>Interfaces</topic><topic>Intestinal microflora</topic><topic>Intestine</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metabolome</topic><topic>Microbiota</topic><topic>NAFLD</topic><topic>NAFLD-HCC</topic><topic>Pathogenesis</topic><topic>Permeability</topic><topic>Weight control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ezzaidi, Niama</creatorcontrib><creatorcontrib>Zhang, Xiang</creatorcontrib><creatorcontrib>Coker, Olabisi Oluwabukola</creatorcontrib><creatorcontrib>Yu, Jun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ezzaidi, Niama</au><au>Zhang, Xiang</au><au>Coker, Olabisi Oluwabukola</au><au>Yu, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2019-09-10</date><risdate>2019</risdate><volume>459</volume><spage>186</spage><epage>191</epage><pages>186-191</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>The gastrointestinal tract represents one of the largest interfaces between the host and environmental factors. It contains a vast and complex community of microbes, forming what is collectively known as the microbiota. This gut microbiota plays a pivotal role in the maintenance of health, and 'dysbiosis' of the gut microbiota, commonly considered as perturbation of microbiota diversity and composition, has been associated with intestinal and extra-intestinal diseases, including non-alcoholic fatty liver disease (NAFLD) and its associated hepatocellular carcinoma (NAFLD-HCC).
In this review, we highlight microbiota dysbiosis and the microbiota-host interactions that link to the pathogenesis of NAFLD and NAFLD-HCC. We discuss the potential therapeutic implications of the gut microbiota in the progression of NAFLD-HCC.
•Gut microbiota plays a mechanistic role in non-alcoholic fatty liver disease (NAFLD). .•Gut microbiota profile is associated with HCC development in NAFLD patients.•Microbe-generated metabolites contribute to NAFLD and NAFLD-HCC pathogenesis. .•Host immune response is involved in gut microbiota-regulated NAFLD and NAFLD-HCC. .•Gut microbiota acts as a potential therapeutic target for NAFLD.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>31185249</pmid><doi>10.1016/j.canlet.2019.114425</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-3222-5824</orcidid><orcidid>https://orcid.org/0000-0001-5008-2153</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2019-09, Vol.459, p.186-191 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_journals_2255719222 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Alcohol Antibiotics Bacteria Chronic illnesses Cytokines Digestive system Drug resistance Dysbacteriosis Environmental factors Fatty liver Gastrointestinal tract Gut microbiota Gut-liver axis Hepatocellular carcinoma Histology Immunity Insulin resistance Interfaces Intestinal microflora Intestine Liver Liver cancer Liver diseases Metabolism Metabolites Metabolome Microbiota NAFLD NAFLD-HCC Pathogenesis Permeability Weight control |
| title | New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T13%3A59%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20insights%20and%20therapeutic%20implication%20of%20gut%20microbiota%20in%20non-alcoholic%20fatty%20liver%20disease%20and%20its%20associated%20liver%20cancer&rft.jtitle=Cancer%20letters&rft.au=Ezzaidi,%20Niama&rft.date=2019-09-10&rft.volume=459&rft.spage=186&rft.epage=191&rft.pages=186-191&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2019.114425&rft_dat=%3Cproquest_cross%3E2255719222%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2255719222&rft_id=info:pmid/31185249&rft_els_id=S0304383519303477&rfr_iscdi=true |